Pharsight

Cinvanti generic

Cinvanti is an anti-emetic drug owned by Heron Therapeutics Inc. This drug, which contains the active ingredient aprepitant, was first authorized for market use on November 9, 2017.

When will Cinvanti generic be available?

The generic version of Cinvanti will likely be available after September 18, 2035. This is due to the expiration of the last patent, which is held by Heron Therapeutics.

Cinvanti uses

Cinvanti is used to treat nausea and vomiting, including the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly or moderately emetogenic cancer chemotherapy. The effectiveness of Cinvanti can be attributed to its active ingredient, aprepitant.

Cinvanti patent expiration

Cinvanti holds a total of 10 patents, none of which have expired. The last patent for Cinvanti is set to expire on September 18, 2035, which is when the Cinvanti generic is expected to be released. Below are the details of the patents:

Cinvanti dosage

Want to ask something?